4D Molecular Therapeutics, Inc. (FDMT)
Free
No email, no account, no signup.
Pulling latest news for 4D Molecular Therapeutics, Inc.…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Gene therapy and biotechnology
Market Cap
$530M
We're already tracking 4D Molecular Therapeutics, Inc. — here are the latest events we've registered
Recent News
- On May 7, 2026, the company reported Q1 2026 financial results and announced that randomization for the Phase 3 4FRONT-1 trial of 4D-150 in wet AMD is complete. Topline data from this trial is expected in the first half of 2027, while two-year data from the PRISM and SPECTRA trials are anticipated in the second half of 2026.
Want to know how this news affects 4D Molecular Therapeutics, Inc.? Order the analysis.
Order analysis – $4.99
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of 4D Molecular Therapeutics, Inc. will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.